User profiles for Michael Sigouros
Michael SigourosWeill Cornell Medicine Verified email at med.cornell.edu Cited by 1488 |
[HTML][HTML] Distinct classes of complex structural variation uncovered across thousands of cancer genome graphs
Cancer genomes often harbor hundreds of somatic DNA rearrangement junctions, many of
which cannot be easily classified into simple (eg, deletion) or complex (eg, chromothripsis) …
which cannot be easily classified into simple (eg, deletion) or complex (eg, chromothripsis) …
[HTML][HTML] Patient derived organoids to model rare prostate cancer phenotypes
A major hurdle in the study of rare tumors is a lack of existing preclinical models. Neuroendocrine
prostate cancer is an uncommon and aggressive histologic variant of prostate cancer …
prostate cancer is an uncommon and aggressive histologic variant of prostate cancer …
[HTML][HTML] Clinical features of neuroendocrine prostate cancer
Background Neuroendocrine prostate cancer (NEPC) is an aggressive variant of prostate
cancer that may arise de novo or in patients previously treated with hormonal therapies for …
cancer that may arise de novo or in patients previously treated with hormonal therapies for …
[HTML][HTML] Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer
Loss of androgen receptor (AR) signaling dependence occurs in approximately 15%–20%
of advanced treatment-resistant prostate cancers, and this may manifest clinically as …
of advanced treatment-resistant prostate cancers, and this may manifest clinically as …
[HTML][HTML] Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer
Despite advances in the development of highly effective androgen receptor (AR)-directed
therapies for the treatment of men with advanced prostate cancer, acquired resistance to such …
therapies for the treatment of men with advanced prostate cancer, acquired resistance to such …
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer
Histologic transformation to small cell neuroendocrine prostate cancer occurs in a subset of
patients with advanced prostate cancer as a mechanism of treatment resistance. …
patients with advanced prostate cancer as a mechanism of treatment resistance. …
Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy
Purpose: The combination of docetaxel chemotherapy and androgen deprivation therapy (ADT)
has become a standard treatment for patients with metastatic prostate cancer. The …
has become a standard treatment for patients with metastatic prostate cancer. The …
Extracellular matrix in synthetic hydrogel‐based prostate cancer organoids regulate therapeutic response to EZH2 and DRD2 inhibitors
Following treatment with androgen receptor (AR) pathway inhibitors, ≈20% of prostate cancer
patients progress by shedding their AR‐dependence. These tumors undergo epigenetic …
patients progress by shedding their AR‐dependence. These tumors undergo epigenetic …
SLFN11 expression in advanced prostate cancer and response to platinum-based chemotherapy
Expression of the DNA/RNA helicase schlafen family member 11 (SLFN11) has been identified
as a sensitizer of tumor cells to DNA-damaging agents including platinum chemotherapy. …
as a sensitizer of tumor cells to DNA-damaging agents including platinum chemotherapy. …
Detecting neuroendocrine prostate cancer through tissue-informed cell-free DNA methylation analysis
Purpose: Neuroendocrine prostate cancer (NEPC) is a resistance phenotype that emerges
in men with metastatic castration-resistant prostate adenocarcinoma (CR-PRAD) and has …
in men with metastatic castration-resistant prostate adenocarcinoma (CR-PRAD) and has …